Overview

• Interius’ approach aims to generate CAR‑T cells inside the body via an intravenous infusion, potentially avoiding preconditioning chemotherapy and complex ex vivo manufacturing.
• Interius’ lead program, INT2104, entered a Phase I trial for B‑cell malignancies in October 2024, with clinical data still early.
• After approval, Interius’ operations are set to merge into Kite’s Philadelphia research team.
• Analysts note potential advantages in speed and access for in‑vivo CAR‑T, while cautioning about safety, limited clinical evidence, and the lack of pre‑dose quality checks.
• The acquisition extends a 2025 push by large drugmakers into in‑vivo cell therapy, following moves by AstraZeneca and AbbVie and rising investment across the field.